Janie Zhang, MD
Medical Oncology · Pittsburgh, PANPI 1861870966
Payments from drug & device makers
Across 61 payments — averaging $5213.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$273K
- Eli Lilly$37K
- Ipsen Biopharmaceuticals, Inc$3K
- Novartis$2K
- AstraZeneca$1K
- Boehringer Ingelheim Pharma GmbH & Co.kg$1K
- plus $978 from 6 others
What the payments were for
- Consulting fees$1,38823%
- Speaking & faculty fees$2,20536%
- Travel & lodging$1,22920%
- Food & beverage$1,04117%
- Education$2474%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 24 | $273,301 |
| Eli Lilly | 1 | $36,800 |
| Ipsen Biopharmaceuticals, Inc | 8 | $2,683 |
| Novartis | 5 | $1,595 |
| AstraZeneca | 2 | $1,494 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 14 | $1,196 |
| Boehringer Ingelheim International GmbH | 1 | $640 |
| Amgen | 2 | $147 |
| Sunovion Pharmaceuticals Inc. | 1 | $80 |
| Beone Medicines USA, Inc. | 1 | $46 |
| Seagen Inc. | 1 | $45 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$318,046 in reported general payments places this provider in the 65th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 32 | $100,267 |
| EliquisApixaban | 23 | $12,834 |
| Prochlorperazine Maleate | 56 | $2,129 |
| Sodium Chloride0.9 % Sodium Chloride | 63 | $777 |
| Dexamethasone | 141 | $573 |
| Ondansetron OdtOndansetron | 60 | $560 |
| Potassium Chloride | 38 | $344 |
| Pantoprazole Sodium | 27 | $241 |
| Mirtazapine | 15 | $159 |
| Oxycodone Hcl | 20 | $158 |
| Ondansetron Hcl | 12 | $135 |
| Olanzapine | 12 | $79 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Pittsburgh
- Adam BrufskyPittsburgh$6M
- John KirkwoodPittsburgh$3.4M
- Melissa BurgessPittsburgh$2.4M
- Nathan BaharyPittsburgh$2.1M
- Jane RaymondPittsburgh$794K
- Ariel Lopez-ChavezPittsburgh$727K
- Ashwin SomasundaramPittsburgh$696K
- Sukhmani PaddaPhiladelphia$25.6M
- Peter O DwyerPhiladelphia$18M
- Margaret von MehrenPhiladelphia$17.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.